Dos monoclonal juntos reduce the risk of hospitalization and death by COVID-19 by 70%

Last week, it was revealed that an attempt by Eli Lilly and Co’s bamlanivimab pharmacy could reduce COVID-19’s risk by 80% for senior citizens’ homes, The new high-profile data report the deaths and deaths from a combination of monoclonal anticonvulsants, which will reduce the risk of hospitalizations and coronavirus death by 70%..

Bamlanivimab and etesevimab together significantly reduced hospitalizations and deaths related to COVID-19 in high-risk patients recently diagnosed, informs the company in a press release.

Information, and 1,035 volunteers had 11 events (2.1%) in patients receiving therapy and 36 events (7.0%) in patients taking placebo, representing a 70% reduction in risk. Hubo diez deaths in total, todas las cuales ocurrieron in patients que tomaron placebo and no death in patients que tomaron bamlanivimab and etesevimab juntos.

Bamlanivimab and etesevimab together also demonstrate major statistical significance in all of the key secondary valuation criteria, which provide a strong evidence that therapy reduces viral load and accelerates resolution.

“These are emotional results, which replicate the positive phase II data in a much larger group of patients, aggregate clinical evidence evidence on paper that can neutralize the neutralizing antipyretics in this pandemic.” According to Daniel Skovronsky, MD, PhD, Lillydirector Scientific President of Lilly Research Laboratories, “while the preliminary nature of Phase II is the result of COVID-19 neutralizing monoclonal anticoagulants, there may be limited acceptance of them. These Phase III data date more than the available evidence”.

The death toll from COVID-19 has been rising all over the world and hospitalizations have hit record levels -agregó-. These data respond to our most notion that bamlanivimab and etesevimab together have the potential to be an important treatment that significantly reduces hospitalization and death in patients with high risk COVID-19”.

And we ensure that “in particular, the 70% reduction in hospitalization deaths observed in this Phase III study of bamlanivimab and etesevimab juntos is consistent with the reduction in hospitalization risk observed in bamlaniv visits of Phase II ”, Skovronsky stated thatonly bamlanivimab is authorized for emergency use by the EU Drugs and Food Administration (FDA) for the treatment of COVID-19 live in moderation in patients of high risk, and he also received authorizations in various additional countries ”.

The combined therapy is being reviewed by the local drug regulator.

In this way, the security profile of bamlanivimab and etesevimab together with the observations of other Phase I, Phase II and Phase III surveys that evaluate these antecedents. If you notice serious adverse events with a similar frequency in the bamlanivimab and etesevimab groups and placebo groups. In addition to clinical trials, Lilly recovers security and efficacy data in more than 4 million participants treated with neutralizing Lillyanticuerpos, which are bamlanivimab alone or bamlanivimab and etesevimab together.

More dates about the studio

According to the investigation, “no benefits of treatment with bamlanivimab were observed in hospitalized patients referred to COVID-19. Monoclonal anticoagulants, such as bamlanivimab, can be associated with clinical results that are administered to hospitalized patients requiring high oxygen or mechanical ventilation with COVID-19”.

“There is a possibility that severe hypersensitivity reactions will occur, including anaphylaxis, with the administration of bamlanivimab -results the laboratory information-. If there are signs and symptoms of a clinically significant hypersensitivity reaction to anaphylaxis, immediately suspend the administration and initiate appropriate medications and / or supportive measures ”.

Assimilation, detail that Eventually, 1% of participants in the BLAZE-1 clinical trial received bamlanivimab 700 mg and placebo fueron nauseas (3% 4%), diarrhea (1% 5%), mareos 3% front to 2%), cephalea (3% vs 2%), prurito (2% vs 1%) and votes (1% vs 3%) ”.

And regarding its use in specific publications such as embarrassments and women during lactation, the information ensures that “there are no sufficient dates regarding the use of bamlanivimab during the embarrassment. Bamlanivimab should only be used during the embarrassment if the potential benefit is the huge risk for the mother and the fetus ”.

Respect for lactation, “there are no data available on the presence of bamlanivimab in human or animal milk, the effects in lactation or the effects in milk production”. “People who are in love with COVID-19 should follow the practice practices with the clinical pains to avoid exposing the baby to COVID-19”, concluded from the laboratory.

SEGUÍ LEYENDO

Een anticuerpo monoclonal mustró reduce the risk of contraindication COVID-19 has 80% in adult adults